Verrica Pharmaceuticals (VRCA) Operating Income (2021 - 2025)
Historic Operating Income for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $1.6 million.
- Verrica Pharmaceuticals' Operating Income rose 10785.84% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.4 million, marking a year-over-year increase of 7887.44%. This contributed to the annual value of -$65.9 million for FY2024, which is 24.33% down from last year.
- Verrica Pharmaceuticals' Operating Income amounted to $1.6 million in Q3 2025, which was up 10785.84% from $1.5 million recorded in Q2 2025.
- In the past 5 years, Verrica Pharmaceuticals' Operating Income ranged from a high of $1.6 million in Q3 2025 and a low of -$23.9 million during Q3 2023
- In the last 5 years, Verrica Pharmaceuticals' Operating Income had a median value of -$9.1 million in 2022 and averaged -$9.9 million.
- Data for Verrica Pharmaceuticals' Operating Income shows a peak YoY increase of 11230.46% (in 2022) and a maximum YoY decrease of 1245000.0% (in 2022) over the last 5 years.
- Quarter analysis of 5 years shows Verrica Pharmaceuticals' Operating Income stood at -$8.5 million in 2021, then increased by 26.67% to -$6.2 million in 2022, then plummeted by 272.5% to -$23.1 million in 2023, then surged by 50.68% to -$11.4 million in 2024, then skyrocketed by 114.26% to $1.6 million in 2025.
- Its Operating Income was $1.6 million in Q3 2025, compared to $1.5 million in Q2 2025 and -$8.1 million in Q1 2025.